Ducloux D, Fournier V, Bresson-Vautrin C, Chalopin J M
Department of Nephrology and Renal Transplantation, Hôpital Saint Jacques, Besançon, France.
Transpl Int. 1998;11(4):312-5. doi: 10.1007/s001470050149.
Post-transplant erythrosis (PTE) develops in 9%-22% of all renal transplant recipients. Defined as a persistently elevated hematocrit (> 0.51), it occurs most commonly during the first 2 years post-transplantation in hypertensive males with excellent allograft function. Several studies have focused on a major role for angiotensin II in PTE pathogenesis, and some case reports have suggested that losartan is an effective treatment for PTE. Nevertheless, its long-term safety and efficiency have not been reported in renal transplant recipients suffering from PTE. We describe four patients successfully treated with losartan for PTE. Hematocrit remained normal for 21, 18, 15, and 15 months, respectively, after the beginning of losartan therapy. Mean erythropoietin concentration was not modified by treatment (17 +/- 3.7 mU/ml vs 17 +/- 3.8 mU/ml) and serum creatinine concentration remained stable. We conclude that losartan is a safe and effective long-term treatment for PTE.
移植后红细胞增多症（PTE）在所有肾移植受者中的发生率为9% - 22%。其定义为血细胞比容持续升高（> 0.51），最常发生在移植后前2年，见于移植肾功能良好的高血压男性患者。多项研究聚焦于血管紧张素II在PTE发病机制中的主要作用，一些病例报告提示氯沙坦是治疗PTE的有效药物。然而，对于患有PTE的肾移植受者，其长期安全性和有效性尚未见报道。我们描述了4例接受氯沙坦成功治疗PTE的患者。氯沙坦治疗开始后，血细胞比容分别在21、18、15和15个月保持正常。治疗前后促红细胞生成素平均浓度未改变（17 ± 3.7 mU/ml对17 ± 3.8 mU/ml），血清肌酐浓度保持稳定。我们得出结论，氯沙坦是治疗PTE的一种安全有效的长期治疗药物。
